111 related articles for article (PubMed ID: 24002581)
1. Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma.
Wang H; Feng Y; Bao Z; Jiang C; Yan W; Wang Y; Zhang C; Liu Y; Zhang Q; Zhang W; Jiang C
Oncol Rep; 2013 Nov; 30(5):2089-96. PubMed ID: 24002581
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion.
Wang H; Wang Y; Bao Z; Zhang C; Liu Y; Cai J; Jiang C
Oncol Rep; 2015 Sep; 34(3):1503-9. PubMed ID: 26165699
[TBL] [Abstract][Full Text] [Related]
3. CAMKK2, Regulated by Promoter Methylation, is a Prognostic Marker in Diffuse Gliomas.
Liu DM; Wang HJ; Han B; Meng XQ; Chen MH; Yang DB; Sun Y; Li YL; Jiang CL
CNS Neurosci Ther; 2016 Jun; 22(6):518-24. PubMed ID: 27012733
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Bao Z; Feng Y; Wang H; Zhang C; Sun L; Yan Z; Liu Q; Guo T; Li M; Yang X; Jiang C; Zhang Q; Jiang T
Oncol Rep; 2014 Jul; 32(1):250-60. PubMed ID: 24842301
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
6. F10 gene hypomethylation, a putative biomarker for glioma prognosis.
Liu X; Tang H; Wang Z; Huang C; Zhang Z; She X; Wu M; Li G
J Neurooncol; 2012 May; 107(3):479-85. PubMed ID: 22160665
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Schliesser MG; Claus R; Hielscher T; Grimm C; Weichenhan D; Blaes J; Wiestler B; Hau P; Schramm J; Sahm F; Weiß EK; Weiler M; Baer C; Schmidt-Graf F; Schackert G; Westphal M; Hertenstein A; Roth P; Galldiks N; Hartmann C; Pietsch T; Felsberg J; Reifenberger G; Sabel MC; Winkler F; von Deimling A; Meisner C; Vajkoczy P; Platten M; Weller M; Plass C; Wick W
Oncotarget; 2016 Dec; 7(50):82028-82045. PubMed ID: 27880937
[TBL] [Abstract][Full Text] [Related]
8. POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis.
Liu X; Tang H; Zhang Z; Li W; Wang Z; Zheng Y; Wu M; Li G
Brain Res; 2011 May; 1391():125-31. PubMed ID: 21439273
[TBL] [Abstract][Full Text] [Related]
9. Coiled-coil domain containing 109B is a HIF1α-regulated gene critical for progression of human gliomas.
Xu R; Han M; Xu Y; Zhang X; Zhang C; Zhang D; Ji J; Wei Y; Wang S; Huang B; Chen A; Zhang Q; Li W; Sun T; Wang F; Li X; Wang J
J Transl Med; 2017 Jul; 15(1):165. PubMed ID: 28754121
[TBL] [Abstract][Full Text] [Related]
10. [Genetic and epigenetic markers of gliomas].
Semenova EV; Filatov MV
Tsitologiia; 2013; 55(5):290-9. PubMed ID: 24592735
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma.
Dong X; Deng Q; Nie X; Zhang M; Jia W; Chen C; Xu C; Xu R
Exp Mol Pathol; 2015 Apr; 98(2):192-9. PubMed ID: 25617528
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
[TBL] [Abstract][Full Text] [Related]
13. Repression of Dok7 expression mediated by DNMT1 promotes glioma cells proliferation.
Hua CD; Bian EB; Chen EF; Yang ZH; Tang F; Wang HL; Zhao B
Biomed Pharmacother; 2018 Oct; 106():678-685. PubMed ID: 29990858
[TBL] [Abstract][Full Text] [Related]
14. [Aberrant expression of sox2 gene in malignant gliomas].
Volnitskiĭ AV; Semenova EV; Shtam TA; Kovalev RA; Filatov MV
Tsitologiia; 2014; 56(7):504-10. PubMed ID: 25696994
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
17. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD
Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344
[TBL] [Abstract][Full Text] [Related]
18. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Waha A; Felsberg J; Hartmann W; von dem Knesebeck A; Mikeska T; Joos S; Wolter M; Koch A; Yan PS; Endl E; Wiestler OD; Reifenberger G; Pietsch T; Waha A
Cancer Res; 2010 Feb; 70(4):1689-99. PubMed ID: 20124482
[TBL] [Abstract][Full Text] [Related]
20. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma.
Ho AL; Koch MJ; Tanaka S; Eichler AF; Batchelor TT; Tanboon J; Louis DN; Cahill DP; Chi AS; Curry WT
J Clin Neurosci; 2016 Sep; 31():99-105. PubMed ID: 27279154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
